DE69110554T2 - Radiopharmazeutische Zusammensetzungen, Verabreichungsmethode und Verfahren zur Herstellung derselben. - Google Patents

Radiopharmazeutische Zusammensetzungen, Verabreichungsmethode und Verfahren zur Herstellung derselben.

Info

Publication number
DE69110554T2
DE69110554T2 DE69110554T DE69110554T DE69110554T2 DE 69110554 T2 DE69110554 T2 DE 69110554T2 DE 69110554 T DE69110554 T DE 69110554T DE 69110554 T DE69110554 T DE 69110554T DE 69110554 T2 DE69110554 T2 DE 69110554T2
Authority
DE
Germany
Prior art keywords
administration
making
same
ligand
frozen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69110554T
Other languages
English (en)
Other versions
DE69110554D1 (de
Inventor
Jaime Simon
Joseph R Garlich
R Keith Frank
Kenneth Mcmillan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dow Chemical Co
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of DE69110554D1 publication Critical patent/DE69110554D1/de
Application granted granted Critical
Publication of DE69110554T2 publication Critical patent/DE69110554T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Developing Agents For Electrophotography (AREA)
DE69110554T 1990-06-18 1991-06-18 Radiopharmazeutische Zusammensetzungen, Verabreichungsmethode und Verfahren zur Herstellung derselben. Expired - Lifetime DE69110554T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53887190A 1990-06-18 1990-06-18

Publications (2)

Publication Number Publication Date
DE69110554D1 DE69110554D1 (de) 1995-07-27
DE69110554T2 true DE69110554T2 (de) 1995-12-14

Family

ID=24148781

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69110554T Expired - Lifetime DE69110554T2 (de) 1990-06-18 1991-06-18 Radiopharmazeutische Zusammensetzungen, Verabreichungsmethode und Verfahren zur Herstellung derselben.

Country Status (32)

Country Link
US (1) US5762907A (de)
EP (1) EP0462787B1 (de)
JP (2) JP3636728B2 (de)
KR (1) KR100219964B1 (de)
CN (1) CN1033143C (de)
AT (1) ATE123955T1 (de)
AU (2) AU651112B2 (de)
BR (2) BR9102579A (de)
CA (1) CA2044812C (de)
CS (1) CS184291A3 (de)
CY (1) CY1891A (de)
DE (1) DE69110554T2 (de)
DK (1) DK0462787T3 (de)
EG (1) EG19862A (de)
ES (1) ES2073678T3 (de)
FI (1) FI101044B (de)
GR (1) GR3017430T3 (de)
HK (1) HK80496A (de)
HU (1) HU226897B1 (de)
IE (1) IE71023B1 (de)
IL (1) IL98536A (de)
IS (1) IS1704B (de)
MC (1) MC2260A1 (de)
NO (1) NO302510B1 (de)
NZ (1) NZ238547A (de)
PH (1) PH30975A (de)
PL (1) PL165699B1 (de)
PT (1) PT97996B (de)
RU (1) RU2095085C1 (de)
SA (1) SA92120343B1 (de)
SK (1) SK279598B6 (de)
ZA (1) ZA914615B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5410043A (en) * 1991-12-06 1995-04-25 Schering Aktiengesellschaft Process for the production of mono-N-substituted tetraaza macrocycles
US5320829A (en) * 1991-12-10 1994-06-14 The Dow Chemical Company Oral compositions for inhibiting plaque formation
DE4218744C2 (de) * 1992-06-04 1997-11-06 Schering Ag Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe
US5405601A (en) * 1993-07-02 1995-04-11 Mallinckrodt Medical Inc. Functionalized tripodal ligands for imaging applications
CN1065769C (zh) * 1997-07-03 2001-05-16 中国原子能科学研究院 一种放射性药物制剂的制备方法
CN1092962C (zh) * 1998-01-26 2002-10-23 贾伟 一种减轻骨及骨关节疾病疼痛的药物
EP1191948A2 (de) * 1999-06-11 2002-04-03 Neorx Corporation Hochdosierte radionuklide komplexe zur knochenmark-unterdrückung
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
AU2002249935A1 (en) 2001-01-08 2002-08-19 Neorx Corporation Radioactively labelled conjugates of phosphonates
US6567492B2 (en) 2001-06-11 2003-05-20 Eastern Isotopes, Inc. Process and apparatus for production of F-18 fluoride
US7018614B2 (en) * 2002-11-05 2006-03-28 Eastern Isotopes, Inc. Stabilization of radiopharmaceuticals labeled with 18-F
ATE473019T1 (de) 2002-11-05 2010-07-15 Ion Beam Applic Sa Stabilisierung von wässerigen zusammensetzungen von 18f-markiertem 2-fluoro-2-deoxy-d-glukose mit ethanol
MA38571B1 (fr) * 2013-05-13 2018-10-31 Vision Global Holdings Ltd Composition pharmaceutique comprenant un agent thérapeutique à base d'hémoglobine modifiée pour un traitement de ciblage du cancer et imagerie diagnostique
HUE062439T2 (hu) 2013-10-07 2023-11-28 Igl Pharma Inc Eljárás nagy tisztaságú terápiás csont szerek elõállítására
KR102458116B1 (ko) 2014-12-04 2022-10-24 지이 헬쓰케어 리미티드 방사성 약제로부터의 아세트알데히드의 제거 방법
RU2593017C1 (ru) * 2015-04-23 2016-07-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ получения радиофармацевтического препарата "астат-211"
CA2986622C (en) * 2015-05-21 2023-01-31 Actinium Pharmaceueuticals, Inc. Infusion administration of conjugated monoclonal antibodies
EP3302496B1 (de) 2015-05-25 2021-01-06 IGL Pharma, Inc. Dotmp-kitformulierungen für radioisotope
RU2757258C1 (ru) * 2020-09-28 2021-10-12 федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский ядерный университет "МИФИ" (НИЯУ МИФИ) Способ получения радиофармацевтического препарата с галлием-68 для визуализации метастазов скелета методом пэт

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018883A (en) * 1975-03-10 1977-04-19 Nichols Institute For Endocrinology Thyroxine (T4) radioimmunoassay
NL7605447A (nl) * 1975-06-26 1976-12-28 Byk Mallinckrodt Chem Prod Radioimmunoproefmethode voor de bepaling van thyroxine.
US4301140A (en) * 1979-12-14 1981-11-17 G. D. Searle & Co. Radiopharmaceutical method for monitoring kidneys
US4341755A (en) * 1980-07-15 1982-07-27 Immuno Nuclear Corporation Parathyroid radioimmunoassay
US4457602A (en) * 1981-04-20 1984-07-03 Olympus Optical Company Ltd. Multiple light emission control system utilizing electronic flashes
US4411881A (en) * 1982-07-12 1983-10-25 New England Nuclear Corporation Composition and method for stabilizing radiolabeled compounds using thiocarbonylated diethylenetriamines
US5059412A (en) * 1984-06-04 1991-10-22 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
IL74902A (en) * 1984-06-04 1990-12-23 Dow Chemical Co Organic amine phosphonic acid complexes with particle-emitting radionuclides for the treatment of calcific tumors
US4898724A (en) * 1984-06-04 1990-02-06 The Dow Chemical Company Organis amine phosphonic acid complexes for the treatment of calcific tumors
US5064633A (en) * 1984-06-04 1991-11-12 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes, their formulations and use
GB8510726D0 (en) * 1985-04-26 1985-06-26 Amersham Int Plc Stabilised radio-labelled compounds
US4752464A (en) * 1985-06-07 1988-06-21 Cadema Medical Products, Inc. Treatment of arthritis, including rheumatoid arthritis, with radioactive isotopes
NZ222304A (en) * 1987-05-18 1990-10-26 Dow Chemical Co Suppression of bone marrow using samarium-153, gadolinium-159 or holmium-166 complexes
US4853209A (en) * 1987-05-18 1989-08-01 The Dow Chemical Company Bone marrow suppressing agents
WO1989000052A1 (en) * 1987-06-30 1989-01-12 Mallinckrodt, Inc. Method for enhancing the safety of metal-ligand chelates as magnetic resonants imaging agents and x-ray contrast agents
US4882142A (en) * 1988-12-19 1989-11-21 The Dow Chemical Company Bone marrow suppressing agents
US4937333A (en) * 1989-08-04 1990-06-26 The Dow Chemical Company Method for purifying aminomethylenephosphonic acids for pharmaceutical use
US5219556A (en) * 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes

Also Published As

Publication number Publication date
AU6455994A (en) 1994-08-04
DK0462787T3 (da) 1995-10-30
JP3636728B2 (ja) 2005-04-06
HU226897B1 (en) 2010-01-28
BR1101169A (pt) 2000-08-08
NO912345L (no) 1991-12-19
AU7847091A (en) 1991-12-19
SA92120343B1 (ar) 2004-01-25
PL165699B1 (pl) 1995-01-31
NZ238547A (en) 1994-05-26
JP2002114712A (ja) 2002-04-16
PL290717A1 (en) 1992-02-24
IE71023B1 (en) 1997-01-15
AU665911B2 (en) 1996-01-18
CN1063615A (zh) 1992-08-19
HU912011D0 (en) 1991-12-30
FI101044B (fi) 1998-04-15
DE69110554D1 (de) 1995-07-27
IL98536A0 (en) 1992-07-15
ES2073678T3 (es) 1995-08-16
NO912345D0 (no) 1991-06-17
CA2044812C (en) 2002-12-31
IE912057A1 (en) 1991-12-18
NO302510B1 (no) 1998-03-16
MC2260A1 (fr) 1993-04-26
CN1033143C (zh) 1996-10-30
FI912933A0 (fi) 1991-06-17
HK80496A (en) 1996-05-17
KR920000334A (ko) 1992-01-29
KR100219964B1 (ko) 1999-09-01
FI912933A (fi) 1991-12-19
AU651112B2 (en) 1994-07-14
CA2044812A1 (en) 1991-12-19
EG19862A (en) 1996-06-30
ATE123955T1 (de) 1995-07-15
IS1704B (is) 1998-12-10
CS184291A3 (en) 1992-02-19
PT97996A (pt) 1992-03-31
US5762907A (en) 1998-06-09
BR9102579A (pt) 1992-01-21
ZA914615B (en) 1993-02-24
GR3017430T3 (en) 1995-12-31
PH30975A (en) 1997-12-23
CY1891A (en) 1996-08-30
RU2095085C1 (ru) 1997-11-10
PT97996B (pt) 1998-11-30
EP0462787B1 (de) 1995-06-21
IS3717A7 (is) 1991-12-19
SK279598B6 (sk) 1999-01-11
IL98536A (en) 1996-10-31
HUT57994A (en) 1992-01-28
EP0462787A1 (de) 1991-12-27
JPH04230224A (ja) 1992-08-19

Similar Documents

Publication Publication Date Title
DE69110554T2 (de) Radiopharmazeutische Zusammensetzungen, Verabreichungsmethode und Verfahren zur Herstellung derselben.
NO883926D0 (no) Fremgangsmaate for fremstilling av stabilisert humanproteinpreparat.
DE68908125D1 (de) Knochenmark unterdrueckende medikamente.
ATE247486T1 (de) Pharmazeutische zusammensetzungen, enthaltend diclofenac und 2-hydroxypropyl-beta-cyclodextrin
SE7706126L (sv) Radioaktivt preparat
BE886453A (fr) Compositions durcissables par l'oxygene comprenant un mercapto-organosiloxane, un compose fer-carbonyle et un acide
DK0397452T3 (da) Hidtil ukendte præparater
NO883520L (no) Fremgangsmaate for fremstilling av et injeksjonspreparat.
KR880013576A (ko) 골수억제 조성물 및 이의 용도
ATE23800T1 (de) Roentgen-sichtbarmachungsmittel.
FR2328453A1 (fr) Peptide marque au 99mtc

Legal Events

Date Code Title Description
8364 No opposition during term of opposition